Drug Patents owned by Alnylam Pharms Inc

1. List of Amvuttra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(7 years ago)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

2. List of Givlaari drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(1 year, 21 days ago)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(10 months from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(1 year, 3 months from now)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
May, 2033

(10 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(7 years ago)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

3. List of Onpattro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(9 months from now)

US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
Nov, 2023

(9 months from now)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations
Oct, 2027

(4 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery
Apr, 2029

(6 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(6 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(7 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

4. List of Oxlumo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(12 years from now)

US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(15 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(7 years ago)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 23, 2027
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in